Psychological Medicine
May 4, 2026
Kristine Rømer Thomsen, B. Thylstrup, Morten Hesse et al.
Abstract Background In recent decades, the potency of cannabis resin increased globally, raising concerns, as higher potency has been associated with increased risk of psychiatric harms at the individual level. The aim here was to examine whether changes over time in the potency of seized cannabis resin samples were associated with psychiatric harms at the population level. Methods Data on...
American Journal of Preventive Medicine
May 4, 2026
Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al.
1 citation
IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...
Clinical Therapeutics
May 1, 2026
D. Valenti, Holly Kailher
PURPOSE Cannabis remains one of the most commonly used psychoactive substances among adolescents, with increasing prevalence of daily use during formative neurodevelopmental years. This preliminary study looks at changes in low spatial frequency contrast sensitivity perception using frequency doubling virtual reality technology (IMMAD-FDT). Early initiation of cannabis use-particularly before...
International Journal of Psychiatry Research
May 1, 2026
HH Ratobimanankasina, HA Razakandrainy, JDC Rasolonjatovo et al.
Background: Comorbidity between schizophrenia and cannabis use is associated with greater clinical complexity, behavioural dyscontrol, repeated admissions, and major social consequences. Published hospital data from Madagascar remain limited. Aim: To describe the epidemiological and clinical profile of patients with schizophrenia associated with reported cannabis use in the Psychiatry...
JAMA Internal Medicine
May 1, 2026
Devan Kansagara, Garth E Terry, Chelsea K Ayers et al.
Cannabis use is common among those with mental health conditions, and many people report using cannabis to manage mental health symptoms. It is important for clinicians to understand the lack of clear benefits of cannabis for mental health conditions and the potential for substantial adverse effects. Overall, the potential benefits of cannabis for mental health conditions remain poorly studied....
Early Intervention in Psychiatry
May 1, 2026
Ilaria Domenicano, Alice Onofrio, Domenico De Donatis et al.
ABSTRACT Aim This study aimed to investigate the association between cannabis use prior to enrollment in a First Episode Psychosis (FEP) program and prognosis, including severity of psychiatric symptoms, type of antipsychotic treatment prescribed, and clinical recovery. Methods A longitudinal cohort study was conducted on patients aged 18–35 diagnosed with affective and non‐affective psychosis...
Nature Mental Health
May 1, 2026
Daniel Bello, Sophia H. Blyth, Rachel A Rabin et al.
Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (‘co-use’) is rising in the general population, but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric...
European Journal of Pain
May 1, 2026
Michael M Morgan, Christa M. Hickey
Many people use cannabis to self-medicate for pain. Little is known about the impact of pain on tolerance and spontaneous withdrawal to delta-9-tetrahydrocannabinal (THC), the primary psychoactive compound in cannabis. Our previous research with the opioid morphine suggests persistent pain will increase the magnitude and duration of THC withdrawal. Male and female Sprague-Dawley rats were...
Psychopharmacology
May 1, 2026
Catherine F Moore, Elise M Weerts
Animal models of cannabinoid self-administration are critical for advancing our understanding of the neurobiology of cannabis use and for developing medications for Cannabis Use Disorder. Use of vapor inhalation models have translational relevance, as the majority of humans who use cannabis do so by inhalation (e.g., smoking, vaporization). Adult male and female Sprague Dawley rats (N = 96,...
JAMA Network Open
May 1, 2026
C Austin Zamarripa, Spencer Lin, Mckenna Klausner et al.
Simultaneous cannabis and alcohol use (co-use) is a public safety concern. Controlled data on the effects of co-ingestion of oral cannabis products (edibles) with alcohol are lacking, despite an increased prevalence of this behavior. To evaluate the individual and interactive effects of cannabis edibles and alcohol on simulated driving and subjective and objective impairment measures. This...
Brain, Behavior, and Immunity
May 1, 2026
Havilah P. Ravula, Barkha J. Yadav-Samudrala, Laith E. Sawaqed et al.
Δ9-tetrahydrocannabinol (THC) has been studied for its neuroprotective benefits in disease and its ability to improve HIV-1-related symptoms in clinical and preclinical models. Chronic THC administration may cause reduced sensitivity to antinociceptive, hypothermic, and anxiolytic effects following acute THC administration, and HIV status may further influence these effects. Thus, the present...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
May 1, 2026
Zachary Anderson, Matthew Gunn, Emily Jones et al.
Cannabis use among young adults has reached the highest levels ever recorded. Evidence indicates that acute Δ9-tetrahydrocannabinol (THC) disrupts brain connectivity. Few studies have examined this on a whole-brain level. We examined the effects of a single moderate dose of THC on resting-state functional brain networks among young adult cannabis users. In a within-subject, double-blind,...
Sleep
May 1, 2026
Denise C. Vidot, Bria-Necole Diggs, Amrit Baral et al.
Abstract Introduction Psychedelic use and interest in its therapeutic potential are rapidly increasing; yet its relationship with insomnia remains poorly understood. This study aims to estimate differences in insomnia severity by type of psychedelic consumed among a cohort of 18-to-35-year olds. Methods Data are from the Herbal Heart Study - Sleep Ancillary (N=100) cannabis consumers....
Journal of Analytical Toxicology
April 30, 2026
Alexandria S. Senetra, Sushobhan Mukhopadhyay, Yi-Hua Chiang et al.
Delta-8-tetrahydrocannabinol (Δ8THC) has been growing in popularity across the United States due to its reported therapeutic benefits, including pain relief, euphoria, relaxation, and mild psychoactive effects, especially in areas where sale of delta-9-tetrahydrocannabinol (Δ9THC) is illegal. Currently, much debate surrounds Δ8THC regarding its regulatory status and whether this compound is...
Frontiers in Psychiatry
April 27, 2026
Valerio Ricci, Alessandro Sarni, Domenico de Berardis et al.
Background and hypothesis Cannabis use initiation during adolescence has increased globally, raising concerns about neurodevelopmental consequences during this critical period when the brain undergoes extensive remodeling in cannabinoid receptor-rich regions. Study design This systematic review examines neurodevelopmental consequences of adolescent cannabis use, focusing on structural brain...
International Journal of Social Psychiatry
April 26, 2026
Valerio Ricci, Giovanni Martinotti, Giuseppe Maina
Distinguishing substance-induced psychotic disorders (SIPD) from primary psychotic disorders with concurrent substance use remains a critical diagnostic challenge for treatment planning and prognostic counseling. To systematically review the clinical phenomenology of SIPD, identify distinguishing symptom patterns, and examine relationships between phenomenology and outcomes. A systematic search...
Translational Psychiatry
April 23, 2026
Jimmy Olusakin, Mahima Dewan, A. Kashyap et al.
Cannabis use during pregnancy is increasing, often to alleviate stress and anxiety, yet the impact of prenatal cannabis exposure alone, or in combination with psychosocial stress on maternal regulation and downstream offspring neurodevelopment remains unclear. Here, we developed a translational rodent model combining prenatal Δ⁹-tetrahydrocannabinol (THC) exposure with chronic psychosocial...
Psychopharmacology
April 23, 2026
Josephine Sena Lumor, Henriette Nyberg, Elisabeth Nerem et al.
Abstract Rationale As cannabis legalization and decriminalization have expanded, it is increasingly perceived as a low-risk substance. Concurrently, the potency of cannabis products and the number of young adults seeking treatment for cannabis use disorder have risen markedly. A growing body of research links early onset, frequent use, and high potency cannabis products to a range of adverse...
medRxiv Preprint Server
April 23, 2026
Giada Lombardi, Grace Blest‐hopley, Martina Maria Tarantini et al.
preprint
Regular cannabis use has been associated with alterations in reward-related neural processes, yet findings remain inconsistent and the relationship between neural activity and behavioural performance is not fully understood. The present study aimed to characterise neural and behavioural correlates of reward processing in regular cannabis users (CU) compared with matched non-users (NU) using the...
Journal of ethnicity in substance abuse
April 22, 2026
Naseem Abdulmohi Alhujaili, O. Ayonrinde
Cannabis use has long been linked to the emergence and worsening of psychotic disorders, particularly among adolescents and young adults. This study aimed to determine the prevalence of cannabis use and its psychiatric associations in youth and young adults enrolled in an Early Psychosis Intervention (EPI) program in Southeast Ontario. A retrospective cross-sectional analysis was conducted on...